Paul Glavine

Paul Glavine discloses dealings in 2 companies, chiefly Cybin Inc. and Helus Pharma Inc. We count 5 filings; the first trade dates from 31 August 2026 and the latest from 30 September 2026.

Every open-market trade on record is a purchase: 4 purchases worth €4.1M, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 1 share grant.

In size, the median ticket on the buying side is €1.0M. Relative to company size, the median is 0.14% of market cap (4 purchases with a known value). Clusters matter here: 2 out of 3 purchases overlapped with buying by a colleague within 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The newest entry dates from 1 October 2026: a share grant, in Helus Pharma Inc. The clock since the last published purchase (11 September 2026) now reads 46 days. Between a trade and the moment it shows up on SEDI, the median delay is 3 days. Until a filing is published, the market cannot know about the trade. Source: insider filings from SEDI. Past trades are no guide to future returns.